Cargando…
A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907678/ https://www.ncbi.nlm.nih.gov/pubmed/29675111 http://dx.doi.org/10.7150/jca.23984 |
_version_ | 1783315582825791488 |
---|---|
author | Wang, Yi Xiao, Xiuying Wang, Tianyi Li, Lin Zhu, Yue Xu, Haiyan Chu, Yuening Jiao, Feng Cui, Jiujie Wang, Liwei |
author_facet | Wang, Yi Xiao, Xiuying Wang, Tianyi Li, Lin Zhu, Yue Xu, Haiyan Chu, Yuening Jiao, Feng Cui, Jiujie Wang, Liwei |
author_sort | Wang, Yi |
collection | PubMed |
description | The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study. The predictive value of pretreatment serum LDH, CA19-9, CRP and ALB levels for OS were evaluated, and the same as combination of the four factors. It was confirmed that serum LDH, CA19-9, CRP and ALB levels were independent prognostic factors for OS by multivariate analyses. The results of Kaplan-Meier analyses revealed that serum LDH, CA19-9, CRP, ALB levels as well as the combination of the four factors were correlated with OS. It's concluded that the combination of the pretreatment serum LDH, CA19-9, CRP and ALB levels is a prognostic factor for advanced PDAC patients. |
format | Online Article Text |
id | pubmed-5907678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-59076782018-04-19 A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma Wang, Yi Xiao, Xiuying Wang, Tianyi Li, Lin Zhu, Yue Xu, Haiyan Chu, Yuening Jiao, Feng Cui, Jiujie Wang, Liwei J Cancer Research Paper The prognostic role of serum LDH, CA19-9, CRP and ALB in PDAC patients are controversial. In contrast to single factor, there is much less information about the prognostic value of the combination of the four factors in locally advanced and metastatic PDAC patients. It's essential to set up a survival model with the combination of tumor metabolism, tumor biomarker, systemic inflammation and nutritional status to eliminate the prognostic inaccuracy in single biomarker. 94 advanced PDAC patients who received palliative chemotherapy from 2009 to 2017 were recruited for this study. The predictive value of pretreatment serum LDH, CA19-9, CRP and ALB levels for OS were evaluated, and the same as combination of the four factors. It was confirmed that serum LDH, CA19-9, CRP and ALB levels were independent prognostic factors for OS by multivariate analyses. The results of Kaplan-Meier analyses revealed that serum LDH, CA19-9, CRP, ALB levels as well as the combination of the four factors were correlated with OS. It's concluded that the combination of the pretreatment serum LDH, CA19-9, CRP and ALB levels is a prognostic factor for advanced PDAC patients. Ivyspring International Publisher 2018-03-22 /pmc/articles/PMC5907678/ /pubmed/29675111 http://dx.doi.org/10.7150/jca.23984 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wang, Yi Xiao, Xiuying Wang, Tianyi Li, Lin Zhu, Yue Xu, Haiyan Chu, Yuening Jiao, Feng Cui, Jiujie Wang, Liwei A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title | A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title_full | A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title_fullStr | A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title_short | A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma |
title_sort | survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907678/ https://www.ncbi.nlm.nih.gov/pubmed/29675111 http://dx.doi.org/10.7150/jca.23984 |
work_keys_str_mv | AT wangyi asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT xiaoxiuying asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT wangtianyi asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT lilin asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT zhuyue asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT xuhaiyan asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT chuyuening asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT jiaofeng asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT cuijiujie asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT wangliwei asurvivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT wangyi survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT xiaoxiuying survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT wangtianyi survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT lilin survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT zhuyue survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT xuhaiyan survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT chuyuening survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT jiaofeng survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT cuijiujie survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma AT wangliwei survivalmodelinlocallyadvancedandmetastaticpancreaticductaladenocarcinoma |